Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

NCT05872295 is registered in ClinicalTrials.gov with Iksuda Therapeutics Ltd. as lead sponsor.

NCT NCT05872295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05872295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors
Lead sponsor
Iksuda Therapeutics Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 14, 2023
Completion date
December 31, 2027
Enrollment
165 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, gastroesophageal-junction cancer